Sydney · Pre-Seed · 2026

We discover and validate next-generation blood-brain barrier delivery platforms — combining deep BBB biology expertise with AI-driven molecular design.

Partner with us Our platform
0%
Of neurotherapeutics fail to cross the BBB
0M+
People living with dementia globally
$0T
Annual economic burden of neurological disease
Scroll
The Challenge

The blood-brain barrier
is medicine's hardest wall

The brain's protective barrier blocks pathogens — but also nearly every therapeutic we try to deliver. Solving this unlocks treatments for conditions that have defeated medicine for decades.

01 — Selective Exclusion
Tight junction proteins, efflux transporters, and restricted transcytosis block the vast majority of therapeutic molecules from reaching brain tissue.
The barrier is exquisitely selective — and ruthlessly effective.
02 — Unmet Need
Alzheimer's, Parkinson's, glioblastoma, and rare neurological disorders remain largely untreatable.
Not because we lack effective molecules, but because we cannot deliver them where they need to go.
03 — New Frontier
Computational modelling of BBB receptor biology is opening unprecedented design space.
Delivery systems built on the brain's own transport machinery — discovered before a single wet-lab experiment.
The Inlier Mechanism
An inlier starts where others are blocked. It moves through the barrier not by force, but by recognition.
Native. Accepted. Delivered.
The Opportunity

A $35 billion market
waiting for a key

The BBB is the single greatest bottleneck in neurotherapeutics. Whoever solves delivery unlocks not just Alzheimer's — but the entire CNS drug pipeline.

$35B+
CNS Drug Delivery by 2030
Driven by aging populations and a deepening pipeline of molecules that work — if they could only reach the brain.
98%
Failure at the Barrier
The chokepoint is delivery, not the molecule itself. A platform that cracks this captures disproportionate value.
$500M+
Platform Licensing Precedents
BBB delivery platforms have commanded nine-figure valuations and licensing deals from major pharma.
The Engine

NeuraPass discovers what
wet lab alone cannot

A computational discovery engine that models BBB biology at molecular resolution — identifying optimal delivery platforms before a single synthesis is committed.

01

Receptor-agnostic mapping

Systematic modelling of BBB transporter and receptor landscapes across multiple pathways — no single target locked in.

02

Multi-scale permeability prediction

From molecular docking dynamics to capillary flow simulation and transcytosis kinetics — all in silico.

03

ML candidate ranking

Prioritisation of carrier-receptor interactions by predicted BBB crossing efficiency — thousands screened, top 1% advanced.

04

Wet-lab validation funnel

Only highest-confidence candidates proceed to 3D BBB-on-chip and in vivo testing — de-risking at every stage.

Development Path

From computation
to clinic

Every candidate NeuraPass identifies follows a rigorous validation ladder — de-risking at each stage before the next dollar is spent.

NeuraPass Discovery

Computational screening of carrier-receptor pairings across the BBB landscape. Thousands of candidates evaluated in silico to identify the highest-confidence architectures for active transcytosis.

In Progress

3D BBB-on-Chip Validation

Physiologically relevant in vitro models with real-time TEER measurement and flow-mimicked cerebral vasculature. Validates barrier integrity, carrier uptake, and transcytosis before animal studies.

In Progress

In Vivo Proof of Concept

BBB crossing and brain parenchyma delivery confirmed in animal models. Pharmacokinetic profiling, biodistribution, and preliminary efficacy readouts.

Planned

IND-Enabling Studies

GLP toxicology, GMP manufacturing scale-up, and regulatory dossier preparation. The bridge from preclinical validation to first-in-human trials.

Planned

Phase I Human Trials

First-in-human safety and proof-of-mechanism. Demonstrating BBB penetration and therapeutic payload delivery in patients with CNS disease.

Planned
The Team

Deep expertise in BBB biology.
Building the team to scale it.

Inlier Neuro is founded on a decade of hands-on drug delivery research. We are now actively assembling the founding team to accelerate from science to product.

Dr. Sachin Kumar
Dr. Sachin Kumar
Founding Scientist · Brain-Targeted Drug Delivery

PhD in Medicine from Western Sydney University, with doctoral research focused on engineering delivery systems to cross the blood-brain barrier for Alzheimer's disease treatment. Deep domain expertise in BBB biology, nanomedicine, and neurotherapeutics — now building the team to scale it.

BBB Biology Drug Delivery Alzheimer's Nanomedicine In Silico Neurotherapeutics
?
You?
Founding Team · Open Role

We are actively recruiting founding team members with deep expertise in computational biology, machine learning for molecular design, and translational drug development. If you are excited by the intersection of AI and neurotherapeutics, we want to hear from you.

Computational Biology ML / Cheminformatics Translational Ops

We are seeking a computational biology lead with expertise in in-silico molecular modelling and a translational operations partner to bridge science and product development. If your colleague with in-silico expertise is interested — or if you know others — reach out.

Computational Biology Lead Translational Operations Partner In-Silico Modelling Expert
Get Involved

We're building something
that matters

We are currently exploring pre-seed funding, accelerator partnerships, and computational biology collaborations. The BBB problem is solvable — and we're solving it.

collaborate@inlierneuro.com Explore our platform